Gene Therapy TRIZ Cases

Selective ADAMTS13 domain retention fits AAV packaging limits while preserving autoregulation and sustained TTP control.

miRNA target sequences linked to a transgene suppress expression in non-target cells, improving cell specificity and reducing off-target effects.

Partially complementary duplex nucleic acids inhibit HCII expression while balancing sequence specificity, stability, and targeted delivery.

Nucleic acid aptamers specifically activate OR2AT4 to support wound healing, hair growth, and antiproliferative effects with better batch consistency.

Ionizable lipid LNPs deliver mRNA evenly to RPE and photoreceptor cells at low doses, avoiding AAV size limits and reducing retinal toxicity.

An RNA ribozyme from Group IIC introns enables sequence-specific DNA and RNA cleavage while avoiding Cas protein size, transfection, and immune issues.

By blocking LEDGF/p75-integrase binding, LEDGINs retarget HIV integration and keep latent reservoirs transcriptionally silent.

Polymeric gel sustains local antisense RNA release at damaged nerves, supporting targeted chromatin remodeling and remyelination.

Multiple AAV serotypes target key tissues to improve clinical translatability of geroprotective gene studies while preserving research efficiency.

Genetically modified mesenchymal stem cells secrete VEGF to restore blood flow and improve limb salvage outcomes in critical limb ischemia patients.

Segmented Pol II and Pol III promoters enable stable co-expression of multiple shRNAs, reducing toxicity from endogenous microRNA competition.

Knocking down TROLL lncRNAs via siRNA or CRISPR/Cas nucleases inhibits PI3K/AKT pathway activation and reduces metastatic progression in TP53-mutated cancers.

Viral vectors encode GLP-1 receptor agonist fusion proteins to achieve sustained expression of therapeutic molecules.

A chimeric nucleic acid molecule uses a splice-sensor sequence to control transgene expression based on MBNL protein activity levels.

miR-548u and miR-548v modulate microtubule dynamics to improve cardiomyocyte relaxation, addressing limited understanding of myocardial regulation mechanisms.

Skeletal muscle specific promoters drive calpain 3 expression via rAAV vectors, resolving cardiotoxicity while improving endurance.

Administering microRNA antagonists reduces scar size and improves ejection fraction while addressing limited endogenous regeneration in ischemic heart disease.

Hypertonic saline boosts gene vector delivery without tissue toxicity, enabling safer cystic fibrosis treatments.

A synthetic modified mRNA system drives transient CCND2 overexpression in cardiomyocytes to activate cell cycle proliferation.

Ribosomal protein-derived 3′-UTR elements enhance mRNA stability and translational efficiency.

Chemically modified double-stranded nucleic acid molecules resist nuclease degradation while maintaining high gene silencing activity.